Tempero Bio raised $70 million in Series B financing led by 8VC, with participation from Aditum Bio, Khosla Ventures, and others.123
Funds will support two Phase 2 clinical trials for TMP-301 in alcohol use disorder (AUD) and cocaine use disorder (CUD).123
TMP-301 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator targeting glutamate signaling to prevent relapse in addiction.35
Preclinical models showed promise for alcohol, cocaine, and opioid use disorders; Phase 1 trial safe in over 80 healthy volunteers.135
No evidence found of Tempero closing or any 'serious' safety event; all recent news highlights positive funding and trial advancements up to March 2025.8
Sources:
1. https://emilyshope.charity/headline/biotech-company-secures-70-million-to-study-addiction-treatment/
2. https://www.biospace.com/business/tempero-raises-70m-to-fight-substance-use-disorders
3. https://www.pharmaceutical-technology.com/news/tempero-secures-70m-to-advance-addiction-treatment-candidate/
5. https://www.biopharmadive.com/news/tempero-bio-substance-abuse-series-b-funding/743305/
8. https://www.prnewswire.com/news-releases/alcohol-use-disorder-market-to-grow-rapidly-at-a-13-6-cagr-by-2034-owing-to-rising-disease-prevalence-significant-advancements-in-genetically-targeted-therapies-along-with-innovative-treatments-such-as-glp-1-receptor-agonists--302621236.html